ClinicalTrials.gg
Not yet recruitingNCT07859124Updated Oct 5, 2026

Whole-Body Vibration and Aerobic Exercise for Primary Dysmenorrhea in Young Adult Women

An interventional study of Whole-Body Vibration Training and Aerobic Exercise Training in Primary Dysmenorrhea, sponsored by Gaziantep Islam Science and Technology University. Not yet recruiting. Open to female participants aged 18 Years to 28 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Gaziantep Islam Science and Technology University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 28 Years
Sex
Female
01

Study summary

The aim of this clinical trial is to learn how whole-body vibration training and aerobic exercise training affect menstrual pain, symptom severity, and quality of life in young adult women with primary dysmenorrhea. Primary dysmenorrhea is menstrual pain that occurs without an underlying medical condition. It can interfere with daily activities and quality of life. Exercise may help manage menstrual pain, but more information is needed about the effects of different exercise approaches.

This study will examine the effects of whole-body vibration training and aerobic exercise training in young adult women with primary dysmenorrhea. Researchers will assess menstrual pain, the severity of menstrual symptoms, and quality of life. The findings may help inform exercise-based approaches to managing primary dysmenorrhea.

Read the detailed description

A total of 66 female student volunteers aged 18-29 years with primary dysmenorrhea who meet the eligibility criteria will be enrolled. Participants will be assigned to one of two groups: the Whole-Body Vibration Training Group (WBV) or the Aerobic Exercise Training Group (AE).

Both exercise programs will last eight weeks and will be conducted three days per week, for a total of 24 sessions. Participants in the WBV group will receive whole-body vibration training, while participants in the AE group will receive aerobic exercise training.

02

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • Primary dysmenorrhea
  • Menstrual pain
  • Whole-body vibration training
  • Aerobic exercise
  • Exercise therapy
03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

This study's planned enrollment of 66 is close to the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Gaziantep Islam Science and Technology University is the lead sponsor of 43 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 28 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-28 years.
  • A female student enrolled in the Physiotherapy Program at the Vocational School of Health Services, Gaziantep Islam Science and Technology University.
  • Reports cramping pain in the lower abdomen during menstruation in at least four menstrual cycles within the past six months.
  • Reports menstrual pain that begins a few hours before or shortly after the onset of menstrual bleeding.
  • Has regular menstrual cycles of 21-35 days, with menstrual bleeding lasting 3-7 days.
  • Has a (BMI) of 18.5-30 kg/m².
  • Is sedentary and does not exercise regularly.
  • Agrees to participate voluntarily and signs the form.
  • Has no mental, psychological, or neurological condition that would prevent them from understanding the assessments.

Exclusion criteria

Exclusion Criteria:

  • A history of a gynecological condition that may cause secondary dysmenorrhea, such as endometriosis, adenomyosis, or pelvic inflammatory disease.
  • Regular use of hormonal medications, oral , or analgesics within the past three months.
  • A history of a systemic or chronic disease, such as cardiovascular disease, thyroid disease, diabetes, or a neurological, endocrine, or rheumatological condition.
  • Smoking or alcohol use.
  • Being a professional athlete or exercising regularly.
  • Pregnancy or breastfeeding.
  • An orthopedic condition or balance problem that prevents exercise, such as vertigo, a fracture within the past six months, or surgery within the past six months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Whole-Body Vibration Training Group

    This programs will last 8 weeks, with exercise sessions 3 days per week.

    Other: Whole-Body Vibration Training

  • Experimental
    Aerobic Exercise Training Group

    This programs will last 8 weeks, with exercise sessions 3 days per week.

    Other: Aerobic Exercise Training

Interventions

  • OtherWhole-Body Vibration Training

    Participants in this group will receive whole-body vibration training three days per week for eight weeks, for a total of 24 sessions. The vibration frequency will be set at 14 Hz and the amplitude at 8 mm. Each session will last approximately 45 minutes.

  • OtherAerobic Exercise Training

    Participants in this group will receive aerobic exercise training three days per week for eight weeks. Each 45-minute session will consist of a 10-minute warm-up, 30 minutes of aerobic exercise, and 5 minutes of cool-down and stretching exercises.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale

    Pain intensity will be assessed using a 10-cm Visual Analog Scale. Participants will mark the point on the line that best represents the intensity of their menstrual pain. The left endpoint represents "no pain," and the right endpoint represents "the worst pain imaginable." The distance from the left endpoint to the mark will be measured in centimeters, yielding a score from 0 to 10. Higher scores indicate more severe pain.

    Time frame: Change from Baseline at 8 weeks

  2. Menstrual Symptom Questionnaire

    The Menstrual Symptom Questionnaire will be used to assess menstrual pain and symptom severity. It is a 24-item scale with five response options for each item. Participants will rate how often they experience each menstruation-related symptom, from 1 ("never") to 5 ("always"). The score is calculated as the mean of the 24 item scores and ranges from 1 to 5. Higher mean scores indicate more severe menstrual symptoms.

    Time frame: Change from Baseline at 8 weeks

Secondary outcomes

  1. 12-Item Short-Form Health Survey

    The 12-Item Short Form Health Survey (SF-12) will be used to assess health-related quality of life. The Mental Component Summary score will be calculated according to the scoring method specified in the study protocol. The SF-12 contains 12 questions covering eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, bodily pain, social functioning, mental health, vitality, and general health. Each domain score ranges from 0 to 100. Higher scores indicate better mental health.

    Time frame: Change from Baseline at 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 10, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859124
Lead sponsor
Gaziantep Islam Science and Technology University
Responsible party
Bengisu Tüfekçi (Assistant Professor, Gaziantep Islam Science and Technology University) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion